Cipla Cuts Down In-House Biosimilars Plans

 
• By Anju Ghangurde
  
Paths
Cipla is rethinking its direction on biosimilars • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip